Bild 1 von 2
Galerie
Bild 1 von 2
The Messenger : Moderna, the Vaccine, and the Business Gamble Tha
Free US Delivery | ISBN:1647823196
US $6,41
Ca.EUR 5,50
Artikelzustand:
“Former library book; may include library markings. Used book that is in excellent condition. May ”... Mehr erfahrenÜber den Artikelzustand
Sehr gut
Buch, das nicht neu aussieht und gelesen wurde, sich aber in einem hervorragenden Zustand befindet. Der Einband weist keine offensichtlichen Beschädigungen auf. Bei gebundenen Büchern ist der Schutzumschlag vorhanden (sofern zutreffend). Alle Seiten sind vollständig vorhanden, es gibt keine zerknitterten oder eingerissenen Seiten und im Text oder im Randbereich wurden keine Unterstreichungen, Markierungen oder Notizen vorgenommen. Der Inneneinband kann minimale Gebrauchsspuren aufweisen. Minimale Gebrauchsspuren. Genauere Einzelheiten sowie eine Beschreibung eventueller Mängel entnehmen Sie bitte dem Angebot des Verkäufers.
- Sofort-KaufenThe Messenger : Moderna, the Vaccine, and the Business Gamble Tha
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
Versand:
Kostenlos Economy Shipping.
Standort: Mishawaka, Indiana, USA
Lieferung:
Lieferung zwischen Di, 19. Aug und Fr, 22. Aug nach 94104 bei heutigem Zahlungseingang
Rücknahme:
30 Tage Rückgabe. Käufer zahlt Rückversand. Wenn Sie ein eBay-Versandetikett verwenden, werden die Kosten dafür von Ihrer Rückerstattung abgezogen.
Zahlungen:
Sicher einkaufen
- Gratis Rückversand im Inland
- Punkte für jeden Kauf und Verkauf
- Exklusive Plus-Deals
Der Verkäufer ist für dieses Angebot verantwortlich.
eBay-Artikelnr.:226765780502
Artikelmerkmale
- Artikelzustand
- Sehr gut
- Hinweise des Verkäufers
- Special Attributes
- EX-LIBRARY
- Publication Name
- Harvard Business Review Press
- ISBN
- 9781647823191
Über dieses Produkt
Product Identifiers
Publisher
Harvard Business Review Press
ISBN-10
1647823196
ISBN-13
9781647823191
eBay Product ID (ePID)
26050390428
Product Key Features
Book Title
Messenger : Moderna, the Vaccine, and the Business Gamble That Changed the World
Number of Pages
320 Pages
Language
English
Publication Year
2022
Topic
Corporate Finance / Venture Capital, Industries / Pharmaceutical & Biotechnology, Economics / General, Research & Development
Genre
Business & Economics
Format
Hardcover
Dimensions
Item Weight
0 Oz
Item Length
9.3 in
Item Width
6.1 in
Additional Product Features
Intended Audience
Trade
LCCN
2022-001931
TitleLeading
The
Dewey Edition
23
Reviews
Advance Praise for The Messenger : " The Messenger delivers a riveting account of Moderna's unprecedented quest to develop a vaccine against Covid-19. With deep reporting and clear writing, Loftus compellingly chronicles the high-stakes drama behind one of the most important science-business stories of our time." -- Ron Winslow, former Deputy Bureau Chief, Health and Science, and award-winning medical reporter, the Wall Street Journal "Peter Loftus's new book is an in-depth look at how a controversial startup whose vaccine was one of the few miracles of the pandemic rose from nothing to a company that at its peak was valued at over $200 billion. The book is part business story, part science story, and entirely a story of people who wouldn't entertain the notion of failure." -- Bethany McLean, contributing editor, Vanity Fair ; columnist, Thomson Reuters; and coauthor, New York Times bestselling author, All the Devils Are Here " The Messenger is a compelling, page-turning story of the development of the mRNA vaccine for Covid-19 by a collaboration between Moderna and scientists at the National Institutes of Health. Given the incredible importance of mRNA vaccines in combating both Covid-19 and other pathogens in the future, this well-written, accessible, and exciting narrative is a must-read." -- Monica Gandhi, MD, MPH; Professor of Medicine and Associate Division Chief, HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, "Offers readers an inside view of the company's ascent from secretive startup to one of the most valuable health care companies in the world." -- Science magazine "Based on nearly 300 interviews with more than 150 people, including Moderna employees, co-founders, members of the company's board and investors past and present, the book tells the story of the bet Moderna made on developing a vaccine for Covid-19." -- Financial Times " Wall Street Journal reporter Loftus charts in his captivating debut Moderna's spectacular rise from a small biotech company with "no products [and] no profits" in 2018 to a key player in the race for a Covid-19 vaccine." -- Publisher's Weekly "A satisfying look at how a smart business can both identify opportunity and do well by doing good." -- Kirkus Reviews Advance Praise for The Messenger : " The Messenger delivers a riveting account of Moderna's unprecedented quest to develop a vaccine against Covid-19. With deep reporting and clear writing, Loftus compellingly chronicles the high-stakes drama behind one of the most important science-business stories of our time." -- Ron Winslow, former Deputy Bureau Chief, Health and Science, and award-winning medical reporter, the Wall Street Journal "Peter Loftus's new book is an in-depth look at how a controversial startup whose vaccine was one of the few miracles of the pandemic rose from nothing to a company that at its peak was valued at over $200 billion. The book is part business story, part science story, and entirely a story of people who wouldn't entertain the notion of failure." -- Bethany McLean, contributing editor, Vanity Fair ; columnist, Thomson Reuters; and coauthor, New York Times bestselling author, All the Devils Are Here " The Messenger is a compelling, page-turning story of the development of the mRNA vaccine for Covid-19 by a collaboration between Moderna and scientists at the National Institutes of Health. Given the incredible importance of mRNA vaccines in combating both Covid-19 and other pathogens in the future, this well-written, accessible, and exciting narrative is a must-read." -- Monica Gandhi, MD, MPH; Professor of Medicine and Associate Division Chief, HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, " Wall Street Journal reporter Peter Loftus provides the inside track on the company in The Messenger , an engagingly pacy yet detailed narrative that traces the scientific origins of the Moderna story through the various dramas that led to the licensing of the vaccine in December 2020." -- The Irish Times "Offers readers an inside view of the company's ascent from secretive startup to one of the most valuable health care companies in the world." -- Science magazine "Based on nearly 300 interviews with more than 150 people, including Moderna employees, co-founders, members of the company's board and investors past and present, the book tells the story of the bet Moderna made on developing a vaccine for Covid-19." -- Financial Times " Wall Street Journal reporter Loftus charts in his captivating debut Moderna's spectacular rise from a small biotech company with "no products [and] no profits" in 2018 to a key player in the race for a Covid-19 vaccine." -- Publisher's Weekly "A satisfying look at how a smart business can both identify opportunity and do well by doing good." -- Kirkus Reviews Advance Praise for The Messenger : " The Messenger delivers a riveting account of Moderna's unprecedented quest to develop a vaccine against Covid-19. With deep reporting and clear writing, Loftus compellingly chronicles the high-stakes drama behind one of the most important science-business stories of our time." -- Ron Winslow, former Deputy Bureau Chief, Health and Science, and award-winning medical reporter, the Wall Street Journal "Peter Loftus's new book is an in-depth look at how a controversial startup whose vaccine was one of the few miracles of the pandemic rose from nothing to a company that at its peak was valued at over $200 billion. The book is part business story, part science story, and entirely a story of people who wouldn't entertain the notion of failure." -- Bethany McLean, contributing editor, Vanity Fair ; columnist, Thomson Reuters; and coauthor, New York Times bestselling author, All the Devils Are Here " The Messenger is a compelling, page-turning story of the development of the mRNA vaccine for Covid-19 by a collaboration between Moderna and scientists at the National Institutes of Health. Given the incredible importance of mRNA vaccines in combating both Covid-19 and other pathogens in the future, this well-written, accessible, and exciting narrative is a must-read." -- Monica Gandhi, MD, MPH; Professor of Medicine and Associate Division Chief, HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, "This book offers a fascinating view inside the company behind the vaccine." -- CHOICE , the publication of the American Library Association "Mr. Loftus' book is an easy and great read for anyone interested in science and business." -- Business Standard " Wall Street Journal reporter Peter Loftus provides the inside track on the company in The Messenger , an engagingly pacy yet detailed narrative that traces the scientific origins of the Moderna story through the various dramas that led to the licensing of the vaccine in December 2020." -- The Irish Times "Offers readers an inside view of the company's ascent from secretive startup to one of the most valuable health care companies in the world." -- Science magazine "Based on nearly 300 interviews with more than 150 people, including Moderna employees, co-founders, members of the company's board and investors past and present, the book tells the story of the bet Moderna made on developing a vaccine for Covid-19." -- Financial Times " Wall Street Journal reporter Loftus charts in his captivating debut Moderna's spectacular rise from a small biotech company with "no products [and] no profits" in 2018 to a key player in the race for a Covid-19 vaccine." -- Publisher's Weekly "A satisfying look at how a smart business can both identify opportunity and do well by doing good." -- Kirkus Reviews Advance Praise for The Messenger : " The Messenger delivers a riveting account of Moderna's unprecedented quest to develop a vaccine against Covid-19. With deep reporting and clear writing, Loftus compellingly chronicles the high-stakes drama behind one of the most important science-business stories of our time." -- Ron Winslow, former Deputy Bureau Chief, Health and Science, and award-winning medical reporter, the Wall Street Journal "Peter Loftus's new book is an in-depth look at how a controversial startup whose vaccine was one of the few miracles of the pandemic rose from nothing to a company that at its peak was valued at over $200 billion. The book is part business story, part science story, and entirely a story of people who wouldn't entertain the notion of failure." -- Bethany McLean, contributing editor, Vanity Fair ; columnist, Thomson Reuters; and coauthor, New York Times bestselling author, All the Devils Are Here " The Messenger is a compelling, page-turning story of the development of the mRNA vaccine for Covid-19 by a collaboration between Moderna and scientists at the National Institutes of Health. Given the incredible importance of mRNA vaccines in combating both Covid-19 and other pathogens in the future, this well-written, accessible, and exciting narrative is a must-read." -- Monica Gandhi, MD, MPH; Professor of Medicine and Associate Division Chief, HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, "Based on nearly 300 interviews with more than 150 people, including Moderna employees, co-founders, members of the company's board and investors past and present, the book tells the story of the bet Moderna made on developing a vaccine for Covid-19." -- Financial Times " Wall Street Journal reporter Loftus charts in his captivating debut Moderna's spectacular rise from a small biotech company with "no products [and] no profits" in 2018 to a key player in the race for a Covid-19 vaccine." -- Publisher's Weekly "A satisfying look at how a smart business can both identify opportunity and do well by doing good." -- Kirkus Reviews Advance Praise for The Messenger : " The Messenger delivers a riveting account of Moderna's unprecedented quest to develop a vaccine against Covid-19. With deep reporting and clear writing, Loftus compellingly chronicles the high-stakes drama behind one of the most important science-business stories of our time." -- Ron Winslow, former Deputy Bureau Chief, Health and Science, and award-winning medical reporter, the Wall Street Journal "Peter Loftus's new book is an in-depth look at how a controversial startup whose vaccine was one of the few miracles of the pandemic rose from nothing to a company that at its peak was valued at over $200 billion. The book is part business story, part science story, and entirely a story of people who wouldn't entertain the notion of failure." -- Bethany McLean, contributing editor, Vanity Fair ; columnist, Thomson Reuters; and coauthor, New York Times bestselling author, All the Devils Are Here " The Messenger is a compelling, page-turning story of the development of the mRNA vaccine for Covid-19 by a collaboration between Moderna and scientists at the National Institutes of Health. Given the incredible importance of mRNA vaccines in combating both Covid-19 and other pathogens in the future, this well-written, accessible, and exciting narrative is a must-read." -- Monica Gandhi, MD, MPH; Professor of Medicine and Associate Division Chief, HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, " Wall Street Journal reporter Loftus charts in his captivating debut Moderna's spectacular rise from a small biotech company with "no products [and] no profits" in 2018 to a key player in the race for a Covid-19 vaccine." -- Publisher's Weekly "A satisfying look at how a smart business can both identify opportunity and do well by doing good." -- Kirkus Reviews Advance Praise for The Messenger : " The Messenger delivers a riveting account of Moderna's unprecedented quest to develop a vaccine against Covid-19. With deep reporting and clear writing, Loftus compellingly chronicles the high-stakes drama behind one of the most important science-business stories of our time." -- Ron Winslow, former Deputy Bureau Chief, Health and Science, and award-winning medical reporter, the Wall Street Journal "Peter Loftus's new book is an in-depth look at how a controversial startup whose vaccine was one of the few miracles of the pandemic rose from nothing to a company that at its peak was valued at over $200 billion. The book is part business story, part science story, and entirely a story of people who wouldn't entertain the notion of failure." -- Bethany McLean, contributing editor, Vanity Fair ; columnist, Thomson Reuters; and coauthor, New York Times bestselling author, All the Devils Are Here " The Messenger is a compelling, page-turning story of the development of the mRNA vaccine for Covid-19 by a collaboration between Moderna and scientists at the National Institutes of Health. Given the incredible importance of mRNA vaccines in combating both Covid-19 and other pathogens in the future, this well-written, accessible, and exciting narrative is a must-read." -- Monica Gandhi, MD, MPH; Professor of Medicine and Associate Division Chief, HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco
Dewey Decimal
338.476153
Synopsis
The inside story of an unprecedented feat of science and business. At the start of 2020, Moderna was a biotech unicorn with dim prospects. Yes, there was the promise of its disruptive innovation that could transform medicine by using something called messenger RNA, one of the body's building blocks of life, to combat disease. But its stock was under water. There were reports of a toxic work culture. And despite ten years of work, the company was still years away from delivering its first product. Investors were getting antsy, or worse, skeptical. Then the pandemic hit, and Moderna, at first reluctantly, became a central player in a global drama--a David to Big Pharma's Goliaths--turning its technology toward breaking the global grip of the terrible disease. By year's end, with the virus raging, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement gave the world a way out of a crippling pandemic while validating Moderna's technology, transforming the company into a global industry power. Biotech, and the venture capital community that fuels it, will never be the same. Wall Street Journal reporter Peter Loftus, veteran reporter covering the pharmaceutical and biotech industries and part of a Pulitzer Prize-finalist team, brings the inside story of Moderna, from its humble start at a casual lunch through its heady startup days, into the heart of the pandemic and beyond. With deep access to all of the major players, Loftus weaves a tale of science and business that brings to life Moderna's monumental feat of creating a vaccine that beat back a deadly virus and changed the business of medicine forever. The Messenger spans a decade and is full of heroic efforts by ordinary people, lucky breaks, and life-and-death decisions. It's the story of a revolutionary idea, the evolution of a cutting-edge American industry, and one of the great achievements of this century., The story of the biotech unicorn in the right place, at the right time, with the right technology. At the start of 2020, Moderna was a waning biotech unicorn, still years away from delivering its first product despite a decade of development of a potentially breakthrough innovation: using RNA to combat disease. Investors were getting antsy or, worse, skeptical. Then the coronavirus pandemic hit, and Moderna became a central player in a global dramaa David to pharma's Goliathsturning its technology toward breaking the global grip of the terrible disease. By year's end, as the outbreak was at its worst, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement not only offered the world a way out of a crippling pandemic but also validated Moderna's gene-based technology, transforming the company into a global industry power, swelling its market value on its prospects for new drugs and vaccines for years to come. Biotech, and the venture capital community that fuels it, will never be the same. Wall Street Journal reporter Peter Loftus, part of a Pulitzer Prize-finalist reporting team and 25-year veteran reporter in the pharmaceutical and biotech industries, brings the inside story of how Moderna went all in on a single revolutionary idea; of quiet research with unknown consequence; of the evolution of a cutting-edge American innovation, industry, and economydecades in the makingthat led to one of the great gambles in business history., The inside story of an unprecedented feat of science and business. At the start of 2020, Moderna was a biotech unicorn with dim prospects. Yes, there was the promise of its disruptive innovation that could transform medicine by using something called messenger RNA, one of the body's building blocks of life, to combat disease. But its stock was under water. There were reports of a toxic work culture. And despite ten years of work, the company was still years away from delivering its first product. Investors were getting antsy, or worse, skeptical. Then the pandemic hit, and Moderna, at first reluctantly, became a central player in a global drama -- a David to Big Pharma's Goliaths -- turning its technology toward breaking the global grip of the terrible disease. By year's end, with the virus raging, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement gave the world a way out of a crippling pandemic while validating Moderna's technology, transforming the company into a global industry power. Biotech, and the venture capital community that fuels it, will never be the same. Wall Street Journal reporter Peter Loftus, veteran reporter covering the pharmaceutical and biotech industries and part of a Pulitzer Prize-finalist team, brings the inside story of Moderna, from its humble start at a casual lunch through its heady startup days, into the heart of the pandemic and beyond. With deep access to all of the major players, Loftus weaves a tale of science and business that brings to life Moderna's monumental feat of creating a vaccine that beat back a deadly virus and changed the business of medicine forever. The Messenger spans a decade and is full of heroic efforts by ordinary people, lucky breaks, and life-and-death decisions. It's the story of a revolutionary idea, the evolution of a cutting-edge American industry, and one of the great achievements of this century.
LC Classification Number
HD9675.V334M645 2022
Artikelbeschreibung des Verkäufers
Rechtliche Informationen des Verkäufers
Info zu diesem Verkäufer
Better World Books
98,8% positive Bewertungen•13,6 Mio. Artikel verkauft
Angemeldet als gewerblicher Verkäufer
Verkäuferbewertungen (4.292.003)
- c***m (426)- Bewertung vom Käufer.Letzter MonatBestätigter KaufAAA+++; Excellent Service; Great Pricing; Fast Delivery-Faster Than Expected to Hawaii , Received 07/27; Paperback book in Great Condition as Described ; TLC Packaging; Excellent Seller Communication, Sends updates . Highly Recommended!, Thank you very much!
- e***g (58)- Bewertung vom Käufer.Letzte 6 MonateBestätigter KaufExcellent prices on used books in great condition. Shipped out quickly. Product condition is accurate to rating in listing. Thanks! NOTE: For this particular book (I ordered several), it came in a soft cover rather than hard cover as the listing stated. I contacted the seller and they responded promptly. They agreed that it was a listing error and provided me with a full refund for this book (without return required) proving they are both a responsible and trustworthy seller.
- 0***1 (1557)- Bewertung vom Käufer.Letzter MonatBestätigter KaufThis book arrived within the time period given and was in the 'very good' condition described. Unfortunately, only being packaged in a plastic bag to traverse the Atlantic meant that all four corners got a battering (I would be happy to pay bit more in future for a bit of cardboard support in packaging) but all in all, the price was good and overall service for books that are difficult to get over here, I am very happy with this purchase and would recommend this seller. Will buy again from them.
Noch mehr entdecken:
- The Face Zeitschriften,
- The Culinary Chronicle Kochbücher,
- Frederick-the-Great-Belletristik - Bücher,
- Frederick-the-Great-Sachbuch Bücher,
- The Walking Dead Belletristik-Bücher,
- Erwachsene Masters of the Universe Hörbücher und Hörspiele,
- Robert-Kirkman-The-Walking - Dead-Belletristik-Bücher,
- Masters of the Universe Jugendliche Hörbücher und Hörspiele,
- Erwachsene Masters of the Universe Hörbücher und Hörspiele,
- Masters of the Universe Buchreihe Hörbücher und Hörspiele mit Kinder- & Jugendliteratur
Better World Books
98,8% positive Bewertungen•13,6 Mio. Artikel verkauft
Angemeldet als gewerblicher Verkäufer
Verkäuferbewertungen (4.292.003)
- c***m (426)- Bewertung vom Käufer.Letzter MonatBestätigter KaufAAA+++; Excellent Service; Great Pricing; Fast Delivery-Faster Than Expected to Hawaii , Received 07/27; Paperback book in Great Condition as Described ; TLC Packaging; Excellent Seller Communication, Sends updates . Highly Recommended!, Thank you very much!
- e***g (58)- Bewertung vom Käufer.Letzte 6 MonateBestätigter KaufExcellent prices on used books in great condition. Shipped out quickly. Product condition is accurate to rating in listing. Thanks! NOTE: For this particular book (I ordered several), it came in a soft cover rather than hard cover as the listing stated. I contacted the seller and they responded promptly. They agreed that it was a listing error and provided me with a full refund for this book (without return required) proving they are both a responsible and trustworthy seller.
- 0***1 (1557)- Bewertung vom Käufer.Letzter MonatBestätigter KaufThis book arrived within the time period given and was in the 'very good' condition described. Unfortunately, only being packaged in a plastic bag to traverse the Atlantic meant that all four corners got a battering (I would be happy to pay bit more in future for a bit of cardboard support in packaging) but all in all, the price was good and overall service for books that are difficult to get over here, I am very happy with this purchase and would recommend this seller. Will buy again from them.